Fengyuan Pharmaceutical's subsidiary, Bengbu Fengyuan Tushan Pharmaceutical, has received approval from China's National Medical Products Administration for its Vunorasan Fumarate chemical raw material. This drug is a potassium-competitive acid blocker (P-CAB) used to treat conditions like reflux esophagitis and Helicobacter pylori infection. In unrelated news, Haiou Co. clarified that its data center cooling tower business constitutes less than 1.5% of its revenue for 2025, and it has no revenue from nuclear power cooling towers. AI
Summary written by gemini-2.5-flash-lite from 1 source. How we write summaries →
RANK_REASON This cluster contains multiple unrelated news items, including a drug approval and a company clarification, presented in a digest format without a clear overarching theme.